JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2003; 41:55-61
© 2003 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cohen, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Cohen, M.

The role of low-molecular-weight heparin in the management of acute coronary syndromes

Marc Cohen, MD, FACC*,*

* Newark Beth Israel Medical Center, Division of Cardiology, Newark, New Jersey, USA



View larger version (23K):

[in a new window]
  		Figure 1 The coagulation cascade. Interaction of the intrinsic pathway (initiated by the activation of Factor XI) and the extrinsic pathway (activated by vascular or tissue injury) results in a cascade of reactions that generate thrombin (Factor IIa). Thrombin is produced from prothrombin Factor II by the action of activated Factor X (Xa). Thrombin then acts on fibrinogen to generate fibrin, which undergoes crosslinking, resulting in a thrombin–fibrin clot.

 


View larger version (27K):

[in a new window]
  		Figure 2 ESSENCE study: One-year follow-up trial results. Significant reductions were found in the composite end point of cardiovascular death, myocardial infarction (MI), and recurrent angina with enoxaparin treatment compared to treatment with unfractionated heparin (UFH). The need for diagnostic catheterization and coronary revascularization was also significantly reduced with enoxaparin treatment. ESSENCE, Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events. Reprinted with permission from the American College of Cardiology Foundation, J Am Coll Cardiol 2000;36:693–8.

 


View larger version (20K):

[in a new window]
  		Figure 3 Meta-analysis of low-molecular-weight heparin (LMWH) trials in unstable angina/non–ST-segment elevation myocardial infarction: ESSENCE, Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events; FRAXIS = FRAXiparine in Ischemic Syndromes; FRIC = FRagmin In unstable Coronary artery disease; LMWH = low-molecular-weight heparin; RRR = relative risk ratio; TIMI = Thrombolysis in Myocardial Infarction; UFH = unfractionated heparin. Adapted from Semin Thromb Hemost 1999;25 Suppl 3:113–21 (Fig. 3), with permission from Thieme Publishers, 2002.

 


View larger version (17K):

[in a new window]
  		Figure 4 Event rates with enoxaparin with or without glycoprotein IIb/IIIa inhibitors in the NICE trials. MI = myocardial infarction; NICE = National Investigators Collaborating on Enoxaparin; TVUR = target vessel urgent revascularization. Kereiakes DJ, Grines C, Fry E. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invas Cardiol 2001;13:272–8. Printed with permission from HMP Communications, 2002. Reprinted with permission from the American College of Cardiology Foundation, J Am Coll Cardiol 2001;37 Suppl A:1A–648A; Abstract 1253–97.

 


View larger version (18K):

[in a new window]
  		Figure 5 Clinical event rates in ACUTE II trial. ACUTE = Antithrombotic Combination Using Tirofiban and Enoxaparin; enox = enoxaparin; MI = myocardial infarction; TIMI = Thrombolysis in Myocardial Infarction; tiro = tirofiban. Cohen M. Anti-thrombotic combination using tirofiban and enoxaparin: the ACUTE II study. Circulation 2000;102:II-826. Reproduced with permission from Lippincott, Williams and Wilkins.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2003 by the American College of Cardiology Foundation.